כישלון בייצור התרופה הפיל את פארמה 2 בי: ביקשה צו פתיחת הליכים
undefined
Sep 3, 2024
www.globenewswire.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
#Acquired-by #Public Trading
Jul 21, 2024
www.fiercebiotech.com
In struggling Hepion, Israeli biotech spies path to go public before seeking FDA approval
#Acquired-by #Investment
Apr 5, 2022
www.globenewswire.com
Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting
#Customers
Dec 15, 2021
www.prnewswire.com
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease
#Investment
Nov 18, 2021
www.globenewswire.com
Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea
#Partners #Investment
Sep 13, 2021
www.globenewswire.com
Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson's Disease
#Customers
Jan 5, 2021
www.globenewswire.com
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer
#Management Changes
Feb 20, 2020
www.globenewswire.com
Pharma Two B Appoints David S. Tierney, M.D. as the Company's Chief Executive Officer
#Management Changes #Expand
Nov 26, 2018
www.prnewswire.com
First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson's Disease
#Investment #Expand
Feb 27, 2017
www.prnewswire.com
Pharma Two B Ltd. Closes $30 Million Financing Round
#Investment
Jun 30, 2015
www.prnewswire.com
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson's Disease
כישלון בייצור התרופה הפיל את פארמה 2 בי: ביקשה צו פתיחת הליכים
undefined
Sep 3, 2024
www.globenewswire.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
#Acquired-by #Public Trading
Jul 21, 2024
www.fiercebiotech.com
In struggling Hepion, Israeli biotech spies path to go public before seeking FDA approval
#Acquired-by #Investment
Apr 5, 2022
www.globenewswire.com
Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting
#Customers
Dec 15, 2021
www.prnewswire.com
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease
#Investment
Nov 18, 2021
www.globenewswire.com
Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea
#Partners #Investment
Sep 13, 2021
www.globenewswire.com
Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson's Disease
#Customers
Jan 5, 2021
www.globenewswire.com
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer
#Management Changes
Feb 20, 2020
www.globenewswire.com
Pharma Two B Appoints David S. Tierney, M.D. as the Company's Chief Executive Officer
#Management Changes #Expand
Nov 26, 2018
www.prnewswire.com
First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson's Disease
#Investment #Expand
Feb 27, 2017
www.prnewswire.com
Pharma Two B Ltd. Closes $30 Million Financing Round
#Investment
Jun 30, 2015
www.prnewswire.com
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson's Disease